AXL and non-small cell lung carcinoma: The combined use of 1 μmol/L linsitinib augmented the effect of osimertinib in AXL-low-expressing EGFR-mutated NSCLC cells (Fig. 5a and Supplementary Fig. 11a), but not in AXL-high-expressing EGFR-mutated PC-9 or HCC4011 cells (Fig. 5b).